Compare Boston Scientific Corporation (BSX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Stryker Corporation — how do they compare? Boston Scientific Corporation trades at $52.92 (market cap $74.52B), while Stryker Corporation trades at $340.75 (market cap $133.18B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays a 1.01% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SYK | |
|---|---|---|
Market Cap | $74.52B | $133.18B |
Sector | Health | Technology |
52-Week High | $108.14 | $394.34 |
52-Week Low | $42.63 | $282.58 |
Enterprise Value | $86.60B | $144.65B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.69, up 0.98% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows strong fundamentals with Q2 2026 EPS of $0.86 beating estimates and revenue growth to $20.07B in 2025, alongside improving net income margins. Analyst sentiment is overwhelmingly positive with 86% buy ratings and a $67.21 consensus price target, though recent news highlights guidance cuts and competitive pressures in key segments like WATCHMAN.
The stock presents a compelling long-term opportunity given robust earnings growth and institutional confidence, but faces near-term risks from execution challenges and market volatility. Upside potential exists if the company stabilizes guidance and leverages new product catalysts, making it attractive for investors with a tolerance for sector-specific headwinds.
Stryker (SYK) trades at $347.21, down 0.27% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 earnings with EPS of $3.69 beating estimates and 9% organic sales growth, reflecting recovery from a cyber incident. Valuation ratios like P/E of 35.98 and P/S of 5.19 indicate a premium, but profitability remains robust with a net income margin of 14.43% and ROE of 16.51%.
Outlook is positive due to earnings momentum and raised guidance, though risks include execution challenges from cyber costs and supply constraints. Analysts are overwhelmingly bullish with 74% buy ratings, suggesting upside potential, but investors should monitor margin pressures and competitive threats in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
